NCT04491734View on ClinicalTrials.gov

Tolerability Study of a Novel Microbiome Therapeutic in Subjects With Gastroesophageal Reflux Disease

NACompletedINTERVENTIONAL

Enrollment

156

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

August 26, 2021

Study Completion Date

August 26, 2021

Conditions

Gastroesophageal Reflux

Interventions

DIETARY_SUPPLEMENT

maltosyl-isomalto-oligosaccharides (MIMO)

Digestion-resistant carbohydrate, ISOT-101, a specific formulation of maltosyl-isomalto-oligosaccharides (MIMO), that serves as a prebiotic, feeding selected bacteria that commonly inhabit the human GI tract.

Trial Locations (1)

20109

ISOThrive Inc., Manassas

All Listed Sponsors

lead

ISOThrive Inc.

INDUSTRY

NCT04491734 - Tolerability Study of a Novel Microbiome Therapeutic in Subjects With Gastroesophageal Reflux Disease | Biotech Hunter | Biotech Hunter